Patient Monitoring & Wearables

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a leading global medtech company, has announced its first-quarter financial results for 2025, reflecting solid performance driven by strategic transformation initiatives. The company’s results indicate continued growth across its core business segments, positioning Baxter for long-term value creation despite global macroeconomic uncertainty.

Strategic Transformation and Focus on Execution

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a global leader in medical technology, will host a conference call on Thursday, May 8, 2025, at 7:30 a.m. Central Time to discuss its first-quarter 2025 financial results. Investors, analysts, and other stakeholders are invited to participate in the call by pre-registering through the provided link to receive the necessary call-in information.

SHERIDAN, WYOMING – May 6, 2025 – The healthcare industry has long relied on traditional training methods for healthcare professionals (HCPs), but recent challenges highlighted by the COVID-19 pandemic have underscored the urgent need for innovation in medical education. Enter Virtual Reality (VR), a transformative tool that is revolutionizing the way healthcare workers are trained and empowering them to deliver better care while improving patient outcomes.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.

Double-Digit Revenue Growth Across Segments and Regions

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for its Simplera Sync™ sensor, marking a significant expansion of its continuous glucose monitoring (CGM) portfolio in the United States. The approval enables integration of the Simplera Sync™ sensor with the company’s flagship MiniMed™ 780G system, offering greater flexibility and convenience to people managing diabetes through advanced insulin delivery technology.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has officially submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) for its MiniMed™ 780G pump and SmartGuard™ algorithm, paving the way for seamless integration with Abbott’s advanced continuous glucose monitoring (CGM) platform. This critical regulatory milestone strengthens Medtronic’s strategic partnership with Abbott and positions the company to deliver more interoperable, intelligent diabetes care solutions to the U.S. market.